New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Indena presents new studies on Boswellia serrata extract

Boswellia serrata
Indena presents new studies on Casperome®, its Boswellia serrata extract formulated with Phytosome® technology.

Yesterday, at the Pharma-Nutrition Conference in Philadelphia, Christian Artaria, marketing director of Indena, made an oral presentation in a plenary session on the outcomes of a recent pharmacokinetic study on Casperome®, the Boswellia serrata extract formulated with the Indena proprietary Phytosome® technology.

Boswellic acids have long been considered the main bioactive components of Boswellia serrata, and many pre-clinical studies have confirmed their bioactivities. In particular, recent mechanistic studies have validated the capacity of the β-boswellic acid family to modulate physiological response to various challenges, but preliminary pharmacokinetic studies in animals and humans have highlighted the poor oral absorption of boswellic acids[1].

To overcome this problem, Indena has formulated a purified mixture of boswellic acids from Boswellia serrata with lecithin, taking advantage of its proprietary Phytosome® technology platform to optimize their absorption. In a previous pre-clinical work such superior absorption was demonstrated both at the plasma and at the tissue level [2].

The randomized, double blind, cross-over comparative pharmacokinetic study in healthy volunteers with a single oral dosage of 500 mg confirmed a marked increase of major boswellic acids in comparison with the unformulated extract[3]. Plasma levels of most relevant boswellic acids measured after Casperome® administration, in particular β-boswellic acids, were in the range of expected biological activity, thus representing strong support for a rational dosage regimen in clinical testing.

Clinical investigations in four controlled studies have given further support to the relevance of this pharmacokinetic study.

Christian Artaria, Marketing Director of Indena, commented: “We are excited for the results we achieved, as for the first time, with a single dosage of 500 mg of Casperome®, relevant plasmatic levels could be reached and measured in humans”.

[1]Du Z. et al. Planta Medica (2015) Feb 25 (under publication)
[2]Hüsch J. et al. Fitoterapia 84 (2013) 89-98
[3]Indena, manuscript submitted for publication


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.